Cargando…

Pneumatocele during sorafenib therapy: first report of an unusual complication

Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangro, Paloma, Bilbao, Idoia, Fernández-Ros, Nerea, Iñarrairaegui, Mercedes, Zulueta, Javier, Bilbao, JI, Sangro, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/
https://www.ncbi.nlm.nih.gov/pubmed/29464101
http://dx.doi.org/10.18632/oncotarget.23599
_version_ 1783300310338371584
author Sangro, Paloma
Bilbao, Idoia
Fernández-Ros, Nerea
Iñarrairaegui, Mercedes
Zulueta, Javier
Bilbao, JI
Sangro, Bruno
author_facet Sangro, Paloma
Bilbao, Idoia
Fernández-Ros, Nerea
Iñarrairaegui, Mercedes
Zulueta, Javier
Bilbao, JI
Sangro, Bruno
author_sort Sangro, Paloma
collection PubMed
description Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib. Patients had no respiratory symptoms and alternative diagnoses were ruled out. Primary tumors were different (liver metastases from a pancreatic neuroendocrine tumor and hepatocellular carcinoma) but both patients had been treated with yttrium 90 radioembolization 9 and 17 months before starting on Sorafenib, respectively. No complications occurred and Sorafenib withdrawal was followed by radiologic improvement.
format Online
Article
Text
id pubmed-5814241
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58142412018-02-20 Pneumatocele during sorafenib therapy: first report of an unusual complication Sangro, Paloma Bilbao, Idoia Fernández-Ros, Nerea Iñarrairaegui, Mercedes Zulueta, Javier Bilbao, JI Sangro, Bruno Oncotarget Case Report Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib. Patients had no respiratory symptoms and alternative diagnoses were ruled out. Primary tumors were different (liver metastases from a pancreatic neuroendocrine tumor and hepatocellular carcinoma) but both patients had been treated with yttrium 90 radioembolization 9 and 17 months before starting on Sorafenib, respectively. No complications occurred and Sorafenib withdrawal was followed by radiologic improvement. Impact Journals LLC 2017-12-22 /pmc/articles/PMC5814241/ /pubmed/29464101 http://dx.doi.org/10.18632/oncotarget.23599 Text en Copyright: © 2018 Sangro et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Sangro, Paloma
Bilbao, Idoia
Fernández-Ros, Nerea
Iñarrairaegui, Mercedes
Zulueta, Javier
Bilbao, JI
Sangro, Bruno
Pneumatocele during sorafenib therapy: first report of an unusual complication
title Pneumatocele during sorafenib therapy: first report of an unusual complication
title_full Pneumatocele during sorafenib therapy: first report of an unusual complication
title_fullStr Pneumatocele during sorafenib therapy: first report of an unusual complication
title_full_unstemmed Pneumatocele during sorafenib therapy: first report of an unusual complication
title_short Pneumatocele during sorafenib therapy: first report of an unusual complication
title_sort pneumatocele during sorafenib therapy: first report of an unusual complication
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/
https://www.ncbi.nlm.nih.gov/pubmed/29464101
http://dx.doi.org/10.18632/oncotarget.23599
work_keys_str_mv AT sangropaloma pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication
AT bilbaoidoia pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication
AT fernandezrosnerea pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication
AT inarrairaeguimercedes pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication
AT zuluetajavier pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication
AT bilbaoji pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication
AT sangrobruno pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication